Parathyroid hormone 7-34

Drug Profile

Parathyroid hormone 7-34

Alternative Names: Parathyroid hormone 7-34 - IGI; PTH (7-34); PTH 7-34; PTHrP (7-34)

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IGI
  • Developer Boston University; Teligent
  • Class Chemoprotectants; Peptide fragments; Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alopecia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia in USA (Topical, Cream)
  • 09 May 2007 IGI receives STTR grant from the US National Cancer Institute for development of PTH 7-34 in chemotherapy-induced Alopecia
  • 13 Dec 2005 IGI has extended its exclusive license from Novavax for the use of Novasome® lipid vesicle encapsulation technology, micellar nanoparticles, and the Ultrasponge® Technology until December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top